Lilly H7T-MC-TADO Paediatric Sickle Cell Disease

• Research type

  Research Study

• Full title

  A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease

• IRAS ID

  119186

• Contact name

  David Rees

• Contact email

  david.rees2@nhs.net

• Sponsor organisation

  Eli Lilly and Company

• Eudract number

  2012-003837-41

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  13/LO/0261

• Date of REC Opinion

  15 Apr 2013

• REC opinion

  Further Information Favourable Opinion